Eupraxia Pharmaceuticals Inc. (EPRX.TO)
CAD 5.51
(0.18%)
CAD 5.51
(0.18%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -11.72 Million CAD | 17.39% |
| 2022 | -14.19 Million CAD | -25.18% |
| 2021 | -11.33 Million CAD | -189.84% |
| 2020 | 12.61 Million CAD | 17.04% |
| 2019 | 10.78 Million CAD | 263.06% |
| 2018 | 2.96 Million CAD | 174.65% |
| 2017 | -3.97 Million CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -35.65 Million CAD | -301.11% |
| 2024 Q2 | -25.52 Million CAD | 47.68% |
| 2023 Q4 | -8.88 Million CAD | 50.04% |
| 2023 Q1 | -8.02 Million CAD | 43.42% |
| 2023 Q3 | -17.79 Million CAD | -123.5% |
| 2023 FY | -11.72 Million CAD | 17.39% |
| 2023 Q2 | -7.96 Million CAD | 0.84% |
| 2022 Q4 | -14.19 Million CAD | -837.66% |
| 2022 Q3 | -1.51 Million CAD | 79.47% |
| 2022 FY | -14.19 Million CAD | -25.18% |
| 2022 Q2 | -7.37 Million CAD | -3.71% |
| 2022 Q1 | -7.1 Million CAD | 37.31% |
| 2021 Q1 | -24.76 Million CAD | -296.22% |
| 2021 FY | -11.33 Million CAD | -189.84% |
| 2021 Q3 | -24.28 Million CAD | 10.83% |
| 2021 Q4 | -11.33 Million CAD | 53.32% |
| 2021 Q2 | -27.23 Million CAD | -10.0% |
| 2020 Q4 | 12.61 Million CAD | 3.36% |
| 2020 Q3 | 12.2 Million CAD | 0.0% |
| 2020 FY | 12.61 Million CAD | 17.04% |
| 2019 FY | 10.78 Million CAD | 263.06% |
| 2019 Q4 | 10.78 Million CAD | 0.0% |
| 2018 FY | 2.96 Million CAD | 174.65% |
| 2017 FY | -3.97 Million CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Appili Therapeutics Inc. | 8.09 Million CAD | 244.888% |
| Helix BioPharma Corp. | -1.08 Million CAD | -984.366% |
| Microbix Biosystems Inc. | -4.96 Million CAD | -136.275% |
| Medicenna Therapeutics Corp. | -16.98 Million CAD | 30.974% |
| Satellos Bioscience Inc. | -22.06 Million CAD | 46.88% |
| Oncolytics Biotech Inc. | -31.11 Million CAD | 62.322% |
| Sernova Corp. | -8.58 Million CAD | -36.529% |